Willow Health

Overview

Willow Health is another cash-pay telehealth platform pulled into the same Eli Lilly 2025 litigation clustering that names Henry Meds, Fella, and related compounder-facing brands. Public coverage frames the suits as a coordinated manufacturer response to compounded semaglutide / tirzepatide marketing that, in Lilly’s view, crosses advertising and competition lines.

For partners, Willow matters less as a unique fact pattern (unless later docket exhibits make it so) and more as confirmation that Lilly did not file a one-off suit against a single outlier. Multiple brands with similar telehealth UX and compounding fulfillment stories appear together — which is how “pattern evidence” is often built in briefings to networks, AGs, and boards.

This desk does not relitigate Lilly’s claims here. We note Willow as a tracked public peer and point partners to dockets and trade summaries for citations.

Why we track it. Cluster peer that reinforces “industry pattern, not one-off brand” framing in compounded GLP-1 enforcement.

Tracked litigation peer — comparative public-record context only.

Public record timeline

1. Apr 2025

   Named alongside peers in Lilly compounded GLP-1 telehealth suit wave

2. Ongoing

   Tracked for docket developments that clarify industry-wide theories